Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease‐based registry (PSOLAR)
Authors:
- A.B. KimballAKA.B. Kimball
- the PSOLAR Steering CommitteeTCthe PSOLAR Steering Committee
Open Access
- 16 July 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 171 (1) , 137-147
Abstract
Psoriasis is associated with several comorbidities and behavioural risk factors. To evaluate demographic and disease characteristics in patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR). PSOLAR is a global, prospective, longitudinal, disease-based registry that includes a postmarketing commitment to evaluate safety in patients with psoriasis. Enrolled patients had to be receiving, or be eligible to receive, conventional systemic or biological agents. Demographic/disease characteristics, medical histories, lifestyle risk factors and previous treatments are collected at enrolment. Efficacy and safety data are collected every 6 months for 8 years, and data are extracted annually. Selected parameters are evaluated by age quartile using post hoc analyses. As of 23 August 2012, 11 900 patients were enrolled at 301 sites in North America, Europe and Latin America. Over half of the PSOLAR population (54·7%) is male, with a mean age of 48·6 years and mean body mass index of 30·9 kg m(-2) at enrolment. Mean duration of disease at enrolment was 17·5 years, and mean Physician's Global Assessment score was 2·0. Psoriatic arthritis (35·5%) and cardiovascular diseases (38·2%) were highly prevalent. Diabetes mellitus type II was reported in 11·4% of patients. Depression and anxiety were noted in 14·7% and 11·1% of patients, respectively; 79·0% reported any alcohol use and 56·7% reported smoking or a history of smoking. The occurrence of most comorbidities, including cardiovascular disease and risk factors, increased with age. In the PSOLAR population, multiple and age-appropriate comorbidities are associated with psoriasis and may affect the selection of psoriasis treatments.Keywords
Funding Information
- Johnson & Johnson Innovative Medicine
This publication has 51 references indexed in Scilit:
- The association between psoriasis and obesity: a systematic review and meta-analysis of observational studiesNutrition & Diabetes, 2012
- Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trialJournal of the American Academy of Dermatology, 2010
- The Risk of Depression, Anxiety, and Suicidality in Patients With PsoriasisArchives of Dermatology, 2010
- The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: A randomized clinical trialJournal of the American Academy of Dermatology, 2010
- Is there truly a risk of lymphoma from biologic therapies?Dermatologic Therapy, 2009
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trialJournal of the American Academy of Dermatology, 2008
- Prevalence of cardiovascular risk factors in patients with psoriasisJournal of the American Academy of Dermatology, 2006
- The Clustering of Other Chronic Inflammatory Diseases in Inflammatory Bowel Disease: A Population-Based StudyGastroenterology, 2005